Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gritstone Grabs $92.7m To Test Personalized Vaccines In Humans

Executive Summary

Gritstone closed a Series B venture capital financing to advance its immunotherapy based on cancer patients' own neoantigens into clinical testing and to explore a new shared antigen platform.


Related Content

Start-Up Quarterly Statistics: Fundraising Fell, But Deal-Making Rose In Q3
Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash
Immuno-Oncology: Sneak Peek Of Preclinical Candidates Waiting In The Wings


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts